ResultsIQ

ResultsIQ › Latest results › CORONA Remedies Limited

CORONA Remedies Limited Q2 FY27 results press release summary

NSE: CORONA · BSE: 544644

Results press release of 30 Oct 2026, summarised by AI from the filing.

CORONA Remedies reports highest ever Q2 FY27 revenue of ₹441.2 cr, up 22.2%, with PAT margin at 13.7% on higher depreciation and amortization.

Key takeaways

  1. Guidance No new guidance; Q2 FY27 revenue growth of 22.2% and H1 FY27 growth of 22% were ahead of the stated guidance.
  2. PAT margin PAT margin fell to 13.7% from 14.5% on higher depreciation and amortization from new facilities and brand acquisitions.
  3. Chronic mix Chronic + Semi Chronic share rose to 71.2% in Q2 FY27 from 67.7% in Q2 FY26, growing ~350 bps faster than the company.
  4. Risk Revenue from newly commissioned facilities and acquired brands is expected to build up only over coming quarters.

Original filing on BSE

CORONA Remedies Limited Q2 FY27 results

As filed: Revenue ₹441 cr, EBITDA ₹96.0 cr, PAT ₹60.2 cr, EBITDA margin 21.8%.

Not scored. No result for the same quarter last year.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹422 cr, EBITDA ₹93.1 cr, PAT ₹60.1 cr, EBITDA margin 22.1%. Not scored. No result for the same quarter last year. Share price after the results: −0.9% in 28 days (Nifty 500: +0.3%).
  • Q4 FY26: Revenue ₹353 cr, EBITDA ₹62.0 cr, PAT ₹45.1 cr, EBITDA margin 17.6%. Not scored. No result for the same quarter last year. Share price after the results: −1.2% in 30 days (Nifty 500: −2.5%).
  • Q3 FY26: Revenue ₹342 cr, EBITDA ₹83.2 cr, PAT ₹41.3 cr, EBITDA margin 24.3%. Not scored. No result for the same quarter last year. Share price after the results: +5.9% in 30 days (Nifty 500: −1.9%).

Past price moves after results do not indicate future moves. Not a recommendation.

CORONA Remedies Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.